期刊文献+

赖诺普利与非洛地平缓释片联用对高血压伴左室肥厚的逆转作用 被引量:1

Effects of the combination therapy with felodipine retard and lisinopril on hypertension and reversion of ventricular remodeling
原文传递
导出
摘要 目的 :观察赖诺普利与非洛地平联用对原发性高血压 (EH)伴左室肥厚 (LVH)的逆转效果。方法 :将 82例EH伴LVH患者随机分为A组 (单用赖诺普利 ) 4 0例 ,B组 (赖诺普利与非洛地平缓释片联用 ) 4 2例。观察两组治疗前后及两组间血压及LVH指标的变化。结果 :6个月后两组血压均较治疗前明显下降 (P <0 .0 1) ,组间降压幅度差异无显著性意义 (P >0 .0 5 ) ;两组左室重量指数均较治疗前明显降低 (P <0 .0 1) ,B组较A组更明显 (P <0 .0 5 )。结论 :两药联用对LVH逆转有协同作用。 Objective:To observe the antihypertensive effect of felodipine retard combined with lisinopril and their effects on reducing left ventricular hypertrophy in essential hypertension (EH). Methods:Eighty two patients with EH were randomly divided into lisinopril treatment group (40 cases) and lisinopril plus felodipine treatment group (42 cases). The indexes of the observation included the variety of blood pressure and left ventricular hypertrophy after 6 months treatment in both groups. Results:It was found that blood pressue was significantly decreased in both groups after 6 months treatment (P< 0.01 ), but no difference was found in the level of blood pressure reduction between these two groups (P> 0.05 ). Index of left ventricular mass reduced significantly in both groups (P< 0.01 ), moreover, this effect was more obvious in the combined treatment group than that in the lisinopril treatment group (P< 0.05 ).Conclusion:Felodipine combined with lisinopril may cause added effect in reduction of left ventricular remodeling.
作者 蔡建华
出处 《临床心血管病杂志》 CAS CSCD 北大核心 2002年第8期373-374,共2页 Journal of Clinical Cardiology
关键词 高血压 赖诺普利 非洛地平 左心室肥厚 Lisinopril Felodipine Hypertension Left ventricular hypertrophy
  • 相关文献

参考文献5

共引文献90

同被引文献23

  • 1刘铁有,王文斌,迟永前,谢玉霞,杨锦华,董树.硝苯吡啶与卡托普利联用逆转左心室肥厚的临床观察[J].齐齐哈尔医学院学报,1996,17(3):178-179. 被引量:1
  • 2李燕.依那普利和硝苯地平联用逆转原发性高血压左心室肥厚的临床观察[J].中国误诊学杂志,2007,7(16):3724-3724. 被引量:5
  • 3Katholi RE,Couri DM. Left ventricular hypertrophy:major risk factor in patients with hypertension:update and practical clinical applications[J].Int J Hypertens,2011,(06):1-10. 被引量:1
  • 4Schmieder RE,Schlaich MP,Klingbeil AU. Update on reversal of leh ventricular hypertrophy in essential hypertension (a metaanalysis of all randomized double-blind studies until December 1996)[J].Nephrology Dialysis Transplantation,1998,(03):564-569. 被引量:1
  • 5Mancia G,Laurent S,Agabiti-Rosei E. Reappraisal of European guidelines on hypertension management:a European Society of Hypertension Task Force document[J].I Hypertens,2009,(11):2121-2158. 被引量:1
  • 6Weder AB. The Avoiding Cardiovascular events through COMbination therapy in Patients Living with Systolic Hypertension (ACCOMPLISH) trial:a comparison of first-line combination therapies[J].Expert Op in Pharmacother,2005,(02):275-281. 被引量:1
  • 7Dahlof B,Sever PS,Pouher NR. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required,in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA):a multicentre randomised controlled trial[J].The Lancet,2005,(9489):895-906. 被引量:1
  • 8Cuspidi C,Sala C,Zanchetti A. Management of hypertension in patients with left ventricular hypertrophy[J].Current Hypertension Reports,2007,(06):498-505. 被引量:1
  • 9Kannel WB. Left ventricular hypertrophy as a risk factor:the Framingham experience[J].Journal of Hypertension Supplement,1991,(02):S3-S8. 被引量:1
  • 10Devereux RB,Wachtell K,Gerdts E. Prognostic Significance of Left Ventricular Mass Change During Treatment of Hypertension[J].Journal of the American Medical Association,2004,(19):2350-2356. 被引量:1

引证文献1

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部